The Food and Drug Administration on Tuesday approved Merck & Co.'s drug Keytruda for the treatment of blood cancer.
The immunotherapy drug, first approved in 2014, can now be used to treat patients with refractory classical Hodgkin lymphoma. Keytruda is already approved to treat head, neck and lung cancers.
The FDA approved this use of the drug through its accelerated approval regulations, which means continued approval for this treatment indication is contingent upon the clinical outcomes of confirmatory clinical trials, according to a company news release.
More articles on supply chain:
7 things to know about Dr. Scott Gottlieb's relationship with the drug industry
Mylan settles biosimilar patent dispute with Roche: 4 things to know
Proposed bill seeks more transparency on PBM rebates